300 related articles for article (PubMed ID: 17034137)
21. Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Doğan H; Doğan ŞD; Gündüz MG; Krishna VS; Lherbet C; Sriram D; Şahin O; Sarıpınar E
Eur J Med Chem; 2020 Feb; 188():112035. PubMed ID: 31951850
[TBL] [Abstract][Full Text] [Related]
22. Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor.
Martínez-Hoyos M; Perez-Herran E; Gulten G; Encinas L; Álvarez-Gómez D; Alvarez E; Ferrer-Bazaga S; García-Pérez A; Ortega F; Angulo-Barturen I; Rullas-Trincado J; Blanco Ruano D; Torres P; Castañeda P; Huss S; Fernández Menéndez R; González Del Valle S; Ballell L; Barros D; Modha S; Dhar N; Signorino-Gelo F; McKinney JD; García-Bustos JF; Lavandera JL; Sacchettini JC; Jimenez MS; Martín-Casabona N; Castro-Pichel J; Mendoza-Losana A
EBioMedicine; 2016 Jun; 8():291-301. PubMed ID: 27428438
[TBL] [Abstract][Full Text] [Related]
23. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis.
Luckner SR; Liu N; am Ende CW; Tonge PJ; Kisker C
J Biol Chem; 2010 May; 285(19):14330-7. PubMed ID: 20200152
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
Lokesh BVS; Prasad YR; Shaik AB
Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
[TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
[TBL] [Abstract][Full Text] [Related]
26. Binding of the tautomeric forms of isoniazid-NAD adducts to the active site of the Mycobacterium tuberculosis enoyl-ACP reductase (InhA): a theoretical approach.
Stigliani JL; Arnaud P; Delaine T; Bernardes-Génisson V; Meunier B; Bernadou J
J Mol Graph Model; 2008 Nov; 27(4):536-45. PubMed ID: 18955002
[TBL] [Abstract][Full Text] [Related]
27. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
Rozwarski DA; Grant GA; Barton DH; Jacobs WR; Sacchettini JC
Science; 1998 Jan; 279(5347):98-102. PubMed ID: 9417034
[TBL] [Abstract][Full Text] [Related]
28. Piperazine derivatives: synthesis, inhibition of the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase and SAR studies.
Rotta M; Pissinate K; Villela AD; Back DF; Timmers LF; Bachega JF; de Souza ON; Santos DS; Basso LA; Machado P
Eur J Med Chem; 2015 Jan; 90():436-47. PubMed ID: 25461892
[TBL] [Abstract][Full Text] [Related]
29. 3D-QSAR studies of arylcarboxamides with inhibitory activity on InhA using pharmacophore-based alignment.
Lu XY; Chen YD; You QD
Chem Biol Drug Des; 2010 Feb; 75(2):195-203. PubMed ID: 20028393
[TBL] [Abstract][Full Text] [Related]
30. Combined effect of epigallocatechin gallate and triclosan on enoyl-ACP reductase of Mycobacterium tuberculosis.
Sharma SK; Kumar G; Kapoor M; Surolia A
Biochem Biophys Res Commun; 2008 Mar; 368(1):12-7. PubMed ID: 17996734
[TBL] [Abstract][Full Text] [Related]
31. Direct inhibitors of InhA are active against Mycobacterium tuberculosis.
Manjunatha UH; S Rao SP; Kondreddi RR; Noble CG; Camacho LR; Tan BH; Ng SH; Ng PS; Ma NL; Lakshminarayana SB; Herve M; Barnes SW; Yu W; Kuhen K; Blasco F; Beer D; Walker JR; Tonge PJ; Glynne R; Smith PW; Diagana TT
Sci Transl Med; 2015 Jan; 7(269):269ra3. PubMed ID: 25568071
[TBL] [Abstract][Full Text] [Related]
32. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
Saharan VD; Mahajan SS
Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
[TBL] [Abstract][Full Text] [Related]
33. Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis.
Stec J; Vilchèze C; Lun S; Perryman AL; Wang X; Freundlich JS; Bishai W; Jacobs WR; Kozikowski AP
ChemMedChem; 2014 Nov; 9(11):2528-37. PubMed ID: 25165007
[TBL] [Abstract][Full Text] [Related]
34. Synthesis of 4-phenoxybenzamide adenine dinucleotide as NAD analogue with inhibitory activity against enoyl-ACP reductase (InhA) of Mycobacterium tuberculosis.
Bonnac L; Gao GY; Chen L; Felczak K; Bennett EM; Xu H; Kim T; Liu N; Oh H; Tonge PJ; Pankiewicz KW
Bioorg Med Chem Lett; 2007 Aug; 17(16):4588-91. PubMed ID: 17560106
[TBL] [Abstract][Full Text] [Related]
35. Investigating the structural basis of arylamides to improve potency against M. tuberculosis strain through molecular dynamics simulations.
Punkvang A; Saparpakorn P; Hannongbua S; Wolschann P; Beyer A; Pungpo P
Eur J Med Chem; 2010 Dec; 45(12):5585-93. PubMed ID: 20888672
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, molecular docking study and biological evaluation of new pyrrole scaffolds as potential antitubercular agents for dual targeting of enoyl ACP reductase and dihydrofolate reductase.
Mahnashi MH; Avunoori S; Gopi S; Shaikh IA; Saif A; Bantun F; Faidah HS; Alhadi AA; Alshehri JH; Alharbi AA; S R PK; Joshi SD
PLoS One; 2024; 19(5):e0303173. PubMed ID: 38739587
[TBL] [Abstract][Full Text] [Related]
37. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
[TBL] [Abstract][Full Text] [Related]
38. Identification of Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors: A combined in-silico and in-vitro analysis.
Lone MY; Athar M; Gupta VK; Jha PC
J Mol Graph Model; 2017 Sep; 76():172-180. PubMed ID: 28734205
[TBL] [Abstract][Full Text] [Related]
39. Chemical synthesis and in silico molecular modeling of novel pyrrolyl benzohydrazide derivatives: Their biological evaluation against enoyl ACP reductase (InhA) and Mycobacterium tuberculosis.
Joshi SD; More UA; Dixit SR; Balmi SV; Kulkarni BG; Ullagaddi G; Lherbet C; Aminabhavi TM
Bioorg Chem; 2017 Dec; 75():181-200. PubMed ID: 28961440
[TBL] [Abstract][Full Text] [Related]
40. A rational approach to identify inhibitors of Mycobacterium tuberculosis enoyl acyl carrier protein reductase.
Chhabria MT; Parmar KB; Brahmkshatriya PS
Curr Pharm Des; 2013; 19(21):3878-83. PubMed ID: 23477735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
